BREAST

 

 

40101 CALGB - CYCLOPHOSPHAMIDE AND DOXORUBICIN (CA) (4 vs. 6 CYCLES) VERSUS PACLITAXEL (4 vs. 6 CYCLES) AS ADJUVANT THERAPY FOR WOMEN WITH NODE-NEGATIVE BREAST CANCER: A 2X2 FACTORIAL PHASE III RANDOMIZED STUDY

 

ECOG PACCT-1 – PROGRAM FOR THE ASSESSMENT OF CLINICAL CANCER TESTS (PACCT-1): TRIAL ASSIGNING INDIVIDUALIZED OPTIONS FOR TREATMENT: THE TAILORX TRIAL

 

IBCSG 24-02 CALGB – PHASE III TRIAL EVALUATING THE ROLE OF OVARIAN FUNCTION SUPRESSION AND THE ROLE OF EXEMESTANE AS ADJUVANT THERAPIES FOR PREMENOPAULSAL WOMEN WITH ENDOCRINE RESPONSIVE BREAST CANCER

 

E1105 CALGB - A RANDOMIZED PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF FIRST-LINE CHEMOTHERAPY AND TRASTUZUMAB WITH OR WITHOUT BEVACIZUMAB FOR PATIENTS WITH HER-2/NEU OVER-EXPRESSING METASTATIC BREAST CANCER

 

E5103 CALGB - A DOUBLE-BLIND PHASE III TRAIL OF DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL WITH BEVACIZUMAB OR PLACEBO IN PATIENTS WITH LYMPH NODE POSITIVE AND HIGH RISK LYMPH NODE NEGATIVE BREAST CANCER

 

N063D CALGB - A RANDOMIZED, MULTI-CENTRE, OPEN-LABEL, PHASE III STUDY OF ADJUVANT LAPATINIB, TRASTUZUMAB, THEIR SEQUENCE AND THEIR COMBINATION IN PATIENTS WITH HER2/ErbB2 POSITIVE PRIMARY BREAST CANCER (NEO-ADJUVANT or ADJUVANT STUDY)

 

06025 ION - A PHASE II STUDY OF ABRAXANE AND NEXAVAR IN THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER

 

TOC4129g PHARMA - A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL VS. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY UNTREATED HER2-POSITIVE METASTATIC BREAST CANCER

 

06031 ION - A PHASE II STUDY OF GEMCITABINE AND BEVACIZUMAB AS FIRST-LINE TREATMENT IN HER2 NEGATIVE, LOCALLY RECURRENT OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TAXANES

 

A6181099 PHARMA - A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER 

 

LPT111110 VEEDA - A PHASE II, SINGLE-ARM, MULTI-CENTER STUDY EVALUATING THE COMBINATION OF VINORELBINE AND LAPATINIB IN WOMEN WITH ErbB2 OVEREXPERSSING METASTATIC BREAST CANCER

 

COLON/RECTAL

 

07041 ION - A MULTI-CENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 CLINICAL TRIAL EVALUATING SAFETY AND EFFICACY OF FOLFIRI WITH EITHER PANITUMUMAB OR BEVACIZUMAB AS SECOND-LINE TREATMENT IN SUBJECTS WITH METASTATIC COLORECTAL CANCER WITH WILD-TYPE KRAS TUMORS

 

07014 ION - A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER

 

80405 CALGB - A PHASE III TRIAL OF IRINOTECAN / 5FU/ LEUCOVORIN OR OXALIPLATIN / 5FU/ LEUCOVORIN WITH BEVACIZUMAB, OR CETUXIMAB (C225), OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM (STUDY ON HOLD)

 

E5204 CALGB - INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOVORIN AND BEVACIZUMAB FOR PATIENTS WITH STAGE II OR III RECTAL CANCER RECEIVING PRE-OPERATIVE CHEMORADIATION

 

N0147 CALGB - A RANDOMIZED PHASE III TRIAL OF OXALIPLATIN (OXAL) PLUS 5-FLUOROURACIL (5-FU)/LEUCOVORIN (CF) WITH OR WITHOUT CETUXIMAB (C225) AFTER CURATIVE RESECTION FOR PATIENTS WITH STAGE III COLON CANCER

 

E5202 CALGB - A RANDOMIZED PHASE III STUDY COMPARING 5-FU, LEUCOVORIN AND OXALIPLATIN VERSUS 5-FU, LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB IN PATIENTS WITH STAGE II COLON CANCER AT HIGH RISK FOR RECURRENCE TO DETERMINE PROSPECTIVELY THE PROGNOSTIC VALUE OF MOLECULAR MARKERS

 

ESOPHAGEAL-GASTRIC

 

80101 CALGB - PHASE III TRIAL OF ADJUVANT CHEMORADIATION AFTER RESECTION OF GASTRIC OR GASTROESOPHAGEAL ADENOCARCINOMA

 

HEAD & NECK

 

20062088 PHARMA - PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTI-CENTER TRIAL OF SECOND-LINE PANITUMUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC OR RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

 

LEUKEMIA

 

10603 CALGB - A PHASE III RANDOMIZED, DOUBLE BLIND STUDY OF INDUCTION (DAUNORUBICIN/CYTARABINE) AND CONSOLIDATION (HIGH-DOSE CYTARBINE) CHEMOTHERAPY + MIDOSTAURIN (PKC412) (IND#101261) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS < 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA

 

E2902 CALGB - A PHASE III RANOMIZED STUDY OF FARNESYL TRANSFERASE INHIBITOR R115777 IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS IN SECOND OR SUBSEQUENT REMISSION OR IN REMISSION AFTER PRIMARY INDUCTION FAILURE OR PATIENTS OVER AGE 60 IN FIRST REMISSION

LUNG

 

07021 ION - A RANDOMIZED, OPEN-LABEL, MULTINATIONAL PHASE III TRIAL COMPARING AMRUBICIN VERSUS TOPOTECAN IN PATIENTS WITH EXTENSIVE OR LIMITED AND SENSITIVE OR REFRACTORY SMALL CELL LUNG CANCER AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

 

06-004 ION - PHASE II RANDOMIZED, OPEN-LABEL STUDY OF CETUXIMAB AND BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER

 

30406 CALGB - A PHASE II RANDOMIZED STUDY OF OSI-774 (ERLOTINIB) WITH OR WITHOUT CARBOPLATIN/PACLITAXEL IN PATIENTS WITH PREVIOUSLY UNTREATED ADENOCARCINOMA OF THE LUNG WHO NEVER SMOKED OR WERE FORMER LIGHT SMOKERS (STUDY IS ON HOLD AS OF 10/27/08)

 

ION 07007 - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB

 

E1505 CALGB - A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR PATIENTS WITH COMPLETELY RESECTED STAGE I B (> 4 CM) - IIIA NON-SMALL CELL LUNG CANCER (NSCLC)

 

MELANOMA

 

GM307 PHARMA - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF DACARBAZINE WITH OR WITHOUT GENASENSE IN CHEMOTHERAPY-NAÏVE SUBJECTS WITH ADVANCED MELANOMA AND LOW LDH (THE AGENDA TRIAL)

 

 

MYELOMA

 

07016 ION - RANDOMIZED PHASE 3b STUDY OF THREE TREATMENT REGIMENS IN SUBJECTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA WHO ARE NOT CONSIDERED CANDIDATES FOR HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION: VELCADE (BORTEZOMIB), THALIDOMIDE, AND DEXAMETHASONE (VTD)VERSUS VELCADE AND DEXAMETHASONE (VD) VERSUS VELCADE, MELPHALAN, AND PREDNISONE (VMP)

 

RENAL

 

E2805 CALGB - A RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL OF ADJUVANT SUNITINIB VERSUS SORAFENIB VERSUS PLACEBO IN PATIENTS WITH RESECTED RENAL CELL CARCINOMA

 

 

3066K1-404-WW - WYETH - PHARMA - (OPEN ONLY TO LAKE HEFNER AND MERCY SITES) A RANDOMIZED TRIAL OF TEMSIROLIMUS VERSUS SORAFENIB AS SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO HAVE FAILED FIRST-LINE SUNITINIB THERAPY

 

VEG108844 - VEEDA 08021- A STUDY OF PAZOPANIB VERSUS SUNITINIB IN THE TERATMENT OF SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

 

A4061032 - PFIZER - AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER:  AXIS TRAIL